XIAP and rheumatoid arthritis: While the IAP inhibitor A-4.10099.1 (ABT) was given intravenously in the Mayer study [21], the XIAP inhibitor (Embelin) used in our study was given via oral gavage, suggesting a potential oral treatment for RA patients.